Biotecnol: USA and EP Patents granted for CAB051 - a novel anti-HER2 mini-antibody
Biotecnol S.A. has announced today that the US Patent and Trademark Office (USPTO) has granted Biotecnol a patent - US 7,585,952 - "Human mini-antibody cytotoxic for tumor cells which express the Erb-B2 receptor", which relates to its anti-HER2 antibody product CAB051.
Biotecnol has also been notified by the European Patent Office (EPO) that it too, has granted a patent to Biotecnol for CAB051 – patent number EP 1432737.
Dr Andrew Kelly, CSO of Biotecnol, said: "We are very pleased with both the USPTO’s and EPO’s decision to grant these two patents. These will greatly strengthen the protection of our novel anti-HER2 antibody. It further adds to Biotecnol’s growing IP portfolio, as part of the company’s strategy to pursue strong, effective intellectual property objectives, in order to protect compounds in its pipeline. We firmly believe that CAB051 has the potential to be a significant product in several oncological indications".
This antibody has shown a significant anti-proliferative effect on HER2 overexpressing breast cancers, with the ability to induce both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effector functions. Some of the key features of CAB051 are its reduced cardiotoxicity and pronounced in vivo efficacy against certain type of HER2-positive tumours that did not respond to current anti-HER2 therapies. CAB051 has shown also synergistic effects with other anti-HER2 antibodies and with anthracyclines, and efficacy in other indications such as gastric and prostate cancers.
Biotecnol is a biotechnology company developing biopharmaceutical products, and has a special focus on the development of novel antibody-based therapeutics to treat life-threatening diseases such as cancer. Biotecnol has a proprietary antibody format, which allows it to develop multi-specific antibodies against various cancer targets. These formats are called Tribodies™. Biotecnol is committed in building value by developing a diverse pipeline of antibody products to address unmet healthcare needs. Biotecnol has a presence in the USA and carries out its product development activities via its fully owned subsidiary Biotecnol Pharmaceuticals Inc.
Through its facilities in Portugal, Biotecnol leverages its business income by establishing in-house partner-led or collaborative programmes, which provides Biotecnol with a strong client-based activity and an established track record. Biotecnol uses its proprietary expression technology, cell line development capabilities, upstream and downstream processing, analytics and QC experience for delivering therapeutic recombinant protein products and processes to support all stages of product development, from early research and preclinical activities to GMP/GLP compliant processes, for biomanufacturing of clinical and ultimately commercial products.
(Biotecnol, 19 May 2010)